The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26167692 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Agamemnon Bakakos und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Asthma, Bronchi, Biological Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe asthma imposes a significant burden on public health worldwide, mainly due to its morbidity and high cost. The management of severe asthma has dramatically changed in the past few years with the introduction of biologics. Zero exacerbations, zero systemic corticosteroids, better asthma control, and better lung function are the outcomes that the era of biologics has made attainable in a large proportion of severe asthmatics, ending up in a better quality of life. Still, even today, the changes at the tissue level that reflect these outcomes are not that clear. As a chronic inflammatory disease, asthma often involves airway remodeling in its severe forms; endobronchial biopsies may provide critical insights into these tissue-level changes before and after biologic treatment. However, bronchoscopy is an invasive tool for severe asthma, thus limiting its use in daily clinical practice. This review focuses on summarizing the changes that biologics exert in biopsies obtained from severe asthmatics under biological treatment, providing an opportunity to shed light on what really happens there where it is not easy to see, and especially on what does not happen in patients under biologics who fail to respond as expected. Moreover, the armamentarium of biomarkers used for making the proper choice in patients eligible for more than one biologic needs to be enriched. Biopsy-related markers could be an ideal adjunct to the current ones—blood eosinophils, FeNO, and IgE—to assist the clinician to choose the right biologic for the right patient with severe asthma to achieve disease remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Respiratory Department, Cavan & Monaghan Hospital & Chronic Disease Management Hub, HSE & RCSI University of Medicine, H12 Y7W1 Cavan, Ireland.
- Royal College of Surgeons in Ireland, University of Medicine & Health Sciences, D02 YN77 Dublin 2, Ireland.
- 2nd Department of Respiratory Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Agamemnon Bakakos, Andriana I Papaioannou, Stelios Loukides, Petros Bakakos
Zitieren
APA
Bakakos, A., Ampazis, D., Papaioannou, A. I., Loukides, S., & Bakakos, P. (2025). The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167692
Vancouver
Bakakos A, Ampazis D, Papaioannou AI, Loukides S, Bakakos P. The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167692
BibTeX
@article{Bakakos2025,
author = {Bakakos, Agamemnon and Ampazis, Dimitrios and Papaioannou, Andriana I and Loukides, Stelios and Bakakos, Petros},
title = {The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26167692}
}
EUVIMED